

28 February 2022

Doctor Care Anywhere Closes A\$11.2m Placement and Launches A\$1m SPP

Highlights

- Successful close of placement raising A\$11.2 million (before costs), supported by institutional, professional and sophisticated investors
- In addition, Doctor Care Anywhere will offer all existing eligible securityholders the opportunity to participate in a security purchase plan which will be capped at A\$1.0 million¹
- Proceeds will be used to support organic growth-related initiatives and working capital

Overview of Capital Raising

Doctor Care Anywhere Group PLC (ASX:DOC, “DOC”, “Doctor Care Anywhere” or “the Company”) is pleased to announce a capital raising comprising a non-underwritten placement of A\$11.2 million (“Placement”) and a non-underwritten security purchase plan of A\$1 million¹ (“SPP”) (the Placement and SPP together, the “Capital Raising”).

The offer price for the Capital Raising is A\$0.31 per new CDI in DOC (“Offer Price”), which represents a:

- 12.7% discount to DOC’s last trading price of \$0.355 per CDI on Friday 25 February 2022 (being the last trading day prior to announcement of the Capital Raising)
- 17.0% discount to DOC’s 5-day volume weighted average price (“VWAP”) of \$0.373 per CDI up to and including Friday 25 February 2022 (being the 5 trading day period ending on the last trading day prior to announcement of the Capital Raising)

Up to approximately 39.4 million new CDIs will be issued under the Capital Raising and all new CDIs issued will rank equally with existing DOC CDIs on issue.

Doctor Care Anywhere intends to use the proceeds from the Capital Raising to support organic growth-related initiatives, working capital and the costs of the offer.

Aurenda Partners Pty Ltd and Bell Potter Securities Limited are acting as joint lead managers to the Capital Raising.

Successful Placement

Doctor Care Anywhere has closed a Placement to institutional, professional and sophisticated investors, raising gross proceeds of A\$11.2 million (before costs), with approximately 36.1 million new CDIs to be issued at the Offer Price, representing 10% of DOC’s existing issued capital. The Placement has been made within DOC’s existing ASX Listing Rule 7.1 capacity.

New CDIs issued under the Placement are expected to settle on Friday 4 March 2022 and commence trading on Monday 7 March 2022.

¹ Doctor Care Anywhere may decide to accept applications (in whole or in part) that result in the SPP raising more or less than this amount in its absolute discretion.

Security Purchase Plan

In addition to the Placement, the Company is pleased to announce an SPP of up to approximately A\$1 million. The SPP will provide eligible holders of CDIs in DOC the opportunity to subscribe for up to A\$30,000 worth of new CDIs at A\$0.31 per new CDI, being at the same price as the Placement. DOC reserves the right to increase the size of the SPP or to scale back applications in its absolute discretion.

Further information in relation to the SPP, including the SPP terms and conditions, will be outlined in a separate SPP offer booklet (**Offer Booklet**) which is expected to be released to ASX and dispatched to eligible securityholders on Monday 7 March 2022. The Offer Booklet will contain instructions on how to participate in the SPP. Completed application forms and payments are due by no later than Monday 21 March 2022.

Indicative timetable*

Date	Event
7:00pm (AEDT) Friday 25 February 2022	Record Date for eligible securityholders to subscribe for new CDIs via the SPP
Monday 28 February 2022	Announcement of the Placement and SPP
Friday 4 March 2022	Settlement of Placement
Monday 7 March 2022	Expected date of issue and allotment of the Placement CDIs and commencement of trading of Placement CDIs on ASX
Monday 7 March 2022	Dispatch of SPP booklet and SPP opening date
5:00pm (AEDT) on Monday 21 March 2022	Closing date for SPP
Thursday 24 March 2022	Announcement of results of the SPP
Monday 28 March 2022	Expected date of issue and allotment of the SPP CDIs
Tuesday 29 March 2022	Expected date of commencement of trading of SPP CDIs on the ASX

*The timetable above is indicative only and subject to change. The commencement of trading of new CDIs is subject to confirmation from the ASX. Unless otherwise specified, all dates and times refer to Australian Eastern Daylight Time. The Company reserves the right to alter the below dates at its full discretion and without prior notice, subject to the ASX Listing Rules, Corporations Act 2001 (Cth) and other applicable laws and regulations. In particular, DOC reserves the right to extend the closing dates for the SPP, to accept late applications under the SPP (either generally or in particular cases) and to withdraw the SPP without prior notice. Any extension of the SPP offer closing date may have a consequential impact on the date that new CDIs are issued and commence trading on the ASX. DOC also reserves the right not to proceed with the SPP in whole or in part at any time prior to allotment and issue of the new CDIs. In that event, the relevant application monies (without interest) will be returned in full to applicants. Applicants are encouraged to submit their personalised acceptance forms as soon as possible after the SPP offer opens.

Other Growth Opportunities

As Doctor Care Anywhere has previously announced, its long-term growth strategy includes inorganic growth opportunities in the form of business acquisitions that deliver better outcomes for patients and payors alike.

The Company continues to actively explore such acquisition opportunities in adjacencies which offer additional scale, complementary clinical pathways for the Company's patients, and/or which enhance the company's capabilities.

The Company is in various stages of negotiations with counterparties in relation to such acquisition opportunities, particularly in the United Kingdom, which are aligned to the Company's existing strategy to link primary and secondary care providers using technology.

Such acquisitions may take the form of a share purchase or asset purchase, and will only be made if they are value accretive to the Company. As there are inherent risks with any business acquisition, there is no guarantee that any such acquisition will occur.

Investor Webcast

Investors are invited to join a webcast presentation at 9.30am (AEDT) on Monday 28 February 2022 hosted by CEO Dr Bayju Thakar and CFO Dan Curran.

Investors who wish to attend can register using the following link:

https://us02web.zoom.us/webinar/register/WN_22bIP4DcT8e1fZ1pYRKkyA

Participants are encouraged to submit questions in advance via:

investorenquiries@doctorcareanywhere.com

- ENDS -

This ASX announcement has been authorised for release by the Board of Directors.

About Doctor Care Anywhere:

Doctor Care Anywhere Group PLC is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence based pathways on its proprietary platform. Doctor Care Anywhere utilises its relationships with health insurers, healthcare providers and corporate customers to connect with patients to deliver a range of telehealth services.

Further Information:
Roger Newby Domestique Consulting – Investor Relations +61 401 278 906
Daniel Curran Chief Financial Officer and Company Secretary company.secretary@doctorcareanywhere.com

Important Notice and Disclaimer

This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of the Company, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the outbreak of COVID-19 and international hostilities. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of the Company’s business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of the Company, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to the Company as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of the Company, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement is not financial product advice and has not taken into account your objectives, financial situation or needs. This announcement has been prepared for release in Australia. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any jurisdiction in which such an offer would be illegal. The new CDIs have not been, nor will be, registered under the U.S. Securities Act of 1933 (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the new CDIs may not be offered or sold, directly or indirectly, to any person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.